Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Savara’s $130m stock offering strengthens cash position ahead of MOLBREEVI launch Savara raises $130 million through stock and warrant sale to fund MOLBREEVI’s rare-disease launch—find out how this deal reshapes its commercialization path. bySoujanya RaviOctober 30, 2025